ライフサイエンスコーパス: P2Y(6) receptor

1 esized and assayed for activity at the human P2Y6 receptor.

2 ptor is a species homologue of the mammalian P2Y6 receptor.

3 mologous to the avian p2y3 receptor than the P2Y6 receptor.

4 at the turkey p2y3 receptor than at the rat P2Y6 receptor.

5 ective, indicating the absence of functional P2Y6 receptors.

6 2 and P2Y4 receptors, and at recombinant rat P2Y6 receptors.

7 e is preferred for ligand recognition by the P2Y(6) receptor.

8 We show that the P2Y(6) receptor, a purinergic G protein-coupled receptor

9 thway in RAW 264.7 macrophages downstream of P2Y(6) receptors activated by the ubiquitous signaling n

10 e that the signaling apparatus downstream of P2Y6 receptor activation is moderately saturable.

11 mpared and combined modifications to enhance P2Y(6) receptor agonist selectivity, including ribose ri

12 -Cp(3)U (23, MRS2957) were potent, selective P2Y(6) receptor agonists (EC(50) of 0.026 and 0.012 micr

13 , and stability of pyrimidine nucleotides as P2Y(6) receptor agonists may be enhanced by modest struc

14 ent, stable, and highly selective P2Y(1) and P2Y(6) receptor agonists, respectively.

15 A being produced upon UDP stimulation of the P2Y6 receptor and that PA levels are tightly regulated.

16 uridine nucleotide-responsive receptors, the P2Y6 receptor and the P2Y4 receptor.

17 nderstanding of molecular recognition at the P2Y6 receptor and will be helpful in designing selective

18 te the P2Y14 receptor over the UDP-activated P2Y6 receptor, and these molecules stimulated phosphoryl

19 d by treatment of the cells with a selective P2Y6 receptor antagonist (MRS2578), which did not interf

20 The present study identifies mouse P2Y6 receptor as a regulator of cardiac development and

21 and MRS2578, an inhibitor of the purinergic P2Y6 receptor, blocked NET formation triggered by MSU cr

22 hairpin RNA-mediated knockdown of CysLT1R or P2Y6 receptors, but not of CysLT2R.

23 by homology screening with radiolabeled P2Y1-P2Y6 receptor cDNAs.

24 P2Y6 receptor could constitute a therapeutic target to r

25 We then observed that loss of P2Y6 receptor enhanced pathological cardiac hypertrophy

26 llowed the clear identification of the human P2Y6 receptor gene.

27 modeling of the uracil nucleotide activated P2Y6 receptor have been studied.

28 e stably expressed this receptor and the rat P2Y6 receptor in 1321N1 human astrocytoma cells.

29 ably favored by the upregulation of P2Y4 and P2Y6 receptors in airway epithelium during sensitization

30 ized tracheas showed slight fluorescence for P2Y6 receptors in epithelium and none for P2Y4 .

31 Moreover, the expression levels of P2Y6 receptors in GC tissues were correlated to tumor si

32 with a large increment in mRNA for P2Y4 and P2Y6 receptors in sensitized animals.

33 The P2Y(6) receptor is a cytoprotective G-protein-coupled re

34 es by ATP and UTP but not by ADP or UDP; the P2Y6 receptor is activated most potently by UDP but weak

35 be helpful in designing selective and potent P2Y6 receptor ligands.

36 tive as either an agonist or antagonist in a P2Y6 receptor-mediated contractile response.

37 with freshly harvested arteries, whereas the P2Y(6) receptor mRNA level was unchanged, and the P2Y(4)

38 The absence of P2Y(6) receptors on CD4(+) cells, but not APCs, was suff

39 Mice conditionally deficient in P2Y(6) receptors [p2ry6 (flox/flox);cre/+ mice] exhibite

40 e-activated human P2Y4 receptor (P2Y4-R) and P2Y6 receptor (P2Y6-R) was studied.

41 yl phosphoesters displayed only intermediate P2Y(6) receptor potency but had enhanced stability in ac

42 Thus, P2Y(6) receptors protect the lung against exuberant alle

43 between C5a and UDP, mediated by the C5a and P2Y6 receptors, required dual receptor occupancy, and af

44 ceptor that is selectively activated by UDP (P2Y6 receptor), selectively activated by UTP (P2Y4 recep

45 study focuses on profiling the PA pool upon P2Y6 receptor signaling manipulation to determine the ma

46 eam events resulting in PA production in the P2Y6 receptor signaling pathway.

47 ptor of C6 glioma cells or on P2Y2, P2Y4, or P2Y6 receptors stably expressed in 1321N1 human astrocyt

48 y for activation of the human P2Y(14) vs the P2Y(6) receptor, such as 2-thio-UDP 4 (EC(50) = 1.92 nM

49 P2Y receptor with 65% identity to mammalian P2Y6 receptors, termed the p2y3 receptor, was recently c

50 human MC line LAD2 all express UDP-selective P2Y6 receptors that cooperate with CysLT1R to promote ce

51 Ncleotides activated P2Y6 receptors to raise cytosolic Ca(2+) concentrations

52 ively, we conclude that nucleotides activate P2Y6 receptors to suppress GC growth through a novel SOC

53 r evidence that demonstrates the presence of P2Y6 receptor transcripts in rat pulmonary arterial smoo

54 expression of mRNA for P2Y1, P2Y2, P2Y4, and P2Y6 receptors was demonstrated in HaCaT cells and diffe

55 te for the first time that the expression of P2Y6 receptors was markedly down-regulated in human GC c

56 Y(2), P2Y(4), and P2Y(11) receptors, but not P2Y(6) receptors, was established using a ring-constrain

57 or was a species homologue of the mammalian P2Y6 receptor, we screened two different human genomic l

58 P2Y(6) receptors were inducibly expressed by lung, lymph

59 Furthermore, the P2Y6 receptor, which displays a uridine nucleotide selec

60 Thus, CysLT1R and P2Y6 receptors, which are coexpressed on many cell types

61 stimulation of P2Y(4) receptors with UTP or P2Y(6) receptors with UDP produced very little I(GIRK) a